Targeting VEGF/VEGFR to Modulate Antitumor Immunity.

Authors:
Ju Yang
Ju Yang
Yeungnam University
Jing Yan
Jing Yan
The Comprehensive Cancer Centre of Drum Tower Hospital
China
Baorui Liu
Baorui Liu
The Comprehensive Cancer Centre of Drum Tower Hospital
China

Front Immunol 2018 3;9:978. Epub 2018 May 3.

The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, China.

In addition to the crucial role in promoting the growth of tumor vessels, vascular endothelial growth factor (VEGF) is also immunosuppressive. VEGF can inhibit the function of T cells, increase the recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and hinder the differentiation and activation of dendritic cells (DCs). Recent studies have investigated the role of antiangiogenic agents in antitumor immunity, especially in recent 3 years. Therefore, it is necessary to update the role of targeting VEGF/VEGFR in antitumor immunity. In this review, we focus on the latest clinical and preclinical findings on the modulatory role of antiangiogenic agents targeting VEGF/VEGFR in immune cells, including effector T cells, Tregs, MDSCs, DCs, tumor-associated macrophages, and mast cells. Our review will be potentially helpful for the development of combinations of angiogenesis inhibitors with immunological modulators.

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.00978DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943566PMC
May 2018
9 Reads

Publication Analysis

Top Keywords

antitumor immunity
12
targeting vegf/vegfr
12
antiangiogenic agents
8
role antiangiogenic
8
cells tregs
8
cells
7
dendritic cells
4
activation dendritic
4
tumor-associated macrophages
4
studies investigated
4
investigated role
4
differentiation activation
4
dcs studies
4
cells dcs
4
mdscs hinder
4
myeloid-derived suppressor
4
immune cells
4
tregs myeloid-derived
4
suppressor cells
4
cells mdscs
4

Similar Publications